Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies.
Langston
J W
JW
California Parkinson's Foundation, San Jose 95128.
D001921:Brain / Q000187:drug effects*; D005609:Free Radicals; D006801:Humans; D008959:Models, Neurological; D008995:Monoamine Oxidase / Q000378:metabolism; D009498:Neurotoxins; D010100:Oxygen / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D012642:Selegiline / Q000627:therapeutic use*
D005609:Free Radicals; D009498:Neurotoxins; D012642:Selegiline; D008995:Monoamine Oxidase; D010100:Oxygen